
Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Your AI-Trained Oncology Knowledge Connection!


Published: October 29th 2015 | Updated: